A New Combination Immunotherapy in Advanced Melanoma

Affiliations

¹ From the Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, and the HPB Surgical Unit, Royal Surrey NHS Foundation Trust, Guildford, and the Department of Surgery and Cancer, Imperial College London, London (A.E.F.), and the Department of Oncology, University of Oxford, and the Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.S.) - all in the United Kingdom.

Editorial

Adam E Frampton et al. N Engl J Med. 2022.

. 2022 Jan 6;386(1):91-92.

doi: 10.1056/NEJMe2116892.

¹ From the Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, and the HPB Surgical Unit, Royal Surrey NHS Foundation Trust, Guildford, and the Department of Surgery and Cancer, Imperial College London, London (A.E.F.), and the Department of Oncology, University of Oxford, and the Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford (S.S.) - all in the United Kingdom.

No abstract available

Comment on

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.